百时美施贵宝Bristol Myers Squibb Co. (BMY) 2014年年度报告「NYSE」.pdf

1、2014|Annual ReportDelivering Transformational Medicines to PatientsLOPQRusty Cline participated in a clinical trial for a new immunotherapy from Bristol-Myers Squibb.The patient stories shared in this Annual Report depict individual patient responses to our medicines or investigational compounds and

2、 are not representative of all patient responses.In addition,there is no guarantee that potential drugs or indications still in development will receive regulatory approval.Since he was frst diagnosed with stage four metastatic melanoma in 2006,Rusty Cline,51,who lives on a horse farm in Purcellvill

3、e,Virginia,has had to endure at least 10 surgeries,including two brain surgeries,as the cancer spread and ravaged his body.He had enrolled in several clinical trials for experimental treatments,but recurrences forced him to leave those studies.In 2012,he was given Yervoy(ipilimumab),which had recent

4、ly been approved as a potential treatment option.But his disease continued to progress.“By September,I had quite a few active tumors that were sticking out of my body.I wasnt able to work he is an IT consultant,and was essentially just waiting to die.And I didnt think the wait would be long,”he reca

5、lls.Yet,his parents and a close friend convinced him to enter one more trial even though it was hundreds of miles from home at Memorial Sloan Kettering Cancer Center in New York City and stood by him throughout his treatments.The study for nivolumab(approved in the U.S.in late 2014 as Opdivo for cer

6、tain patients with metastatic melanoma)sought to determine whether his immune system could be activated to fght the disease,even after failing on other treatments.After eight weeks,scans showed a 23 percent reduc-tion in Rustys tumors.And he reports that today the tumors have shrunk by about 95 perc